Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kaoru Okamoto is active.

Publication


Featured researches published by Kaoru Okamoto.


Journal of Medicinal Chemistry | 1997

Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids

Yasuhiro Nagaki; Akira Ishii; Yukari Konishi; Hisashi Yago; Seishi Suehiro; Nobuhisa Okukado; Kaoru Okamoto

Accumulation of intracellular sorbitol, the reduced product of glucose, catalyzed by aldose reductase (AR) (EC 1.1.1.21), is thought to be the cause of the development of diabetic complications. Our attention is focused on finding compounds which inhibit AR without significantly inhibiting aldehyde reductase (ALR) (EC 1.1.1.2). The uracil or 2,4-dioxoimidazolidine skeleton having the benzothiazolyl or 4-chloro-3-nitrophenyl group as an aryl part indicated not only extremely high AR inhibitory activity but also AR selectivity. The ratio of IC50(ALR)/IC50(AR) of 3-[(5-chlorobenzothiazol-2-yl)methyl]-1,2,3,4-tetrahydro-2,4- dioxopyrimidine-1-acetic acid (47d) was more than 17 500. The uracil skeleton with the benzothiazolyl moiety seemed to be the best combination for selective AR inhibition.


Journal of Medicinal Chemistry | 1996

Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids.

Akira Ishii; Yasuhiro Nagaki; Yoji Shibayama; Yoshio Toyomaki; Nobuhisa Okukado; Kazuharu Ienaga; Kaoru Okamoto


Chemical & Pharmaceutical Bulletin | 2002

A new nonpeptide tachykinin NK1 receptor antagonist isolated from the plants of Compositae.

Atsushi Yamamoto; Ko Nakamura; Kazuhito Furukawa; Yukari Konishi; Takashi Ogino; Kunihiko Higashiura; Hisashi Yago; Kaoru Okamoto; Masanori Otsuka


Archive | 1999

MAILLARD REACTION-INHIBITING AGENT

Taisuke Hasegawa; Kazuo Kuwabara; Ko Nakamura; Yoshitaka Nakazawa; Kaoru Okamoto; 耕 中村; 良隆 中澤; 馨 岡本; 和男 桑原; 泰介 長谷川


Archive | 1995

Parabanic acid derivatives

Kaoru Okamoto; Yasuhiro Nagaki


Chemical & Pharmaceutical Bulletin | 1992

3β-Hydroxysialic Acid Glycosides. I. Calcium-Binding Ability and Chemical and Enzymatic Stabilities

Kaoru Okamoto; Taisuke Hasegawa; Yoshio Toyomaki; Masahiro Yamakawa; Nobuhisa Okukado


Archive | 1995

Carboxyalkyl heterocyclic derivatives.

Kaoru Okamoto; Yasuhiro Nagaki


Archive | 2005

Optically active (R)-hydantoin derivative

Kaoru Okamoto; Akira Ishii; Nobuhisa Okukado; Hirohide Matsuura; Mitsuru Naiki; Kazuyoshi Sawada


Archive | 2003

Crystal form of 5-hydroxy-1-methylimidazolidin-2,4-dione

Kaoru Okamoto; Naoharu Nishimura; Akira Ishii


Chemical & Pharmaceutical Bulletin | 1997

Highly Selective Aldose Reductase Inhibitors. II. Optimization of the Aryl Part of 3-(Arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic Acids.

Akira Ishii; Yasuhiro Nagaki; Yoshio Toyomaki; Hisashi Yago; Seishi Suehiro; Nobuhisa Okukado; Kaoru Okamoto

Collaboration


Dive into the Kaoru Okamoto's collaboration.

Top Co-Authors

Avatar

Yoshio Toyomaki

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kunihiko Higashiura

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takashi Ogino

Dokkyo Medical University

View shared research outputs
Top Co-Authors

Avatar

Mitsuru Naiki

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge